The initial months of the COVID-19 pandemic were dominated by studies reporting poor and varied outcomes in patients who developed severe acute respiratory distress syndrome (ARDS) associated with the disease. Variable mortality could have been related to heterogeneity in patient populations and pre-pandemic intensive care infrastructure, resource constraints imposed during the pandemic, and variability in duration of follow-up. As the pandemic has evolved, lower mortality attributable to the disease has been reported. For instance, in a cohort of 742 patients with COVID-19-associated ARDS from Spain, mortality for severe ARDS was 39%,[@bib1] similar to findings of a large epidemiological study of patients with severe ARDS who did not have COVID-19.[@bib2]

Early reports also suggested that patients with severe ARDS associated with COVID-19 should not receive venovenous extracorporeal membrane oxygenation (ECMO) because mortality ranged from 84--100% in patients treated with ECMO. In *The Lancet Respiratory Medicine*, Matthieu Schmidt and colleagues[@bib3] present a cohort study of 83 patients (median age 49 \[IQR 41--56\] years; 61 \[73%\] men) who received ECMO for severe ARDS associated with COVID-19 in the Paris--Sorbonne University Hospital Network intensive care units (ICUs). Their results showed an estimated 31% (95% CI 22--42) probability of death at 60 days, which is similar to that seen in studies of ECMO for severe ARDS outside the pandemic.[@bib4] However, 24% of patients were still in the ICU on day 60. Notably, patients received outstanding pre-ECMO management with high adherence to evidence-based ARDS practices, including prone-positioning in 78 (94%) patients. During ECMO, lung-protective ventilation was achieved with median tidal volumes of 2·5 (IQR 1·8--4·2) mL/kg of predicted bodyweight, the median driving pressure decreased from 18 (IQR 16--21) cm H~2~O pre-ECMO to 12 (12--14) cm H~2~O on ECMO day 1, and there was an approximate 75% decrease in mechanical power (24·7 \[IQR 22·0--27·3\] J/min pre-ECMO to 6·1 \[4·1--11·0\] J/min on ECMO day 1).

The outcome data appear impressive given that the patients represent a very severe subset of ARDS (median PaO~2~/FiO~2~ 60 \[IQR 54--68\] mm Hg), while receiving a median applied positive end-expiratory pressure of 14 (IQR 12--14) cmH~2~O, and were similar to or sicker than ECMO-treated patients with ARDS not associated with COVID-19 reported in the EOLIA trial in 2018.[@bib4] However, it is difficult to draw valid conclusions from comparisons with historical data, especially given that these patients were substantially younger than previously reported patients with severe ARDS associated with COVID-19, and increased age is a well supported risk factor for mortality. Furthermore, although the data are encouraging, the results might not be generalisable, as they come primarily from one highly experienced ECMO centre, and there is a known relationship between hospital-level volume of ECMO cases and patient outcomes when using ECMO.[@bib5]

The authors suggest that ECMO should be considered for patients with COVID-19 with profound respiratory failure despite optimised conventional care. Although this conclusion is reasonable, much remains unknown about the role of ECMO in ARDS associated with COVID-19, including the patients who would benefit the most (or those that would be harmed), long-term outcomes, and the cost-to-benefit ratio. It is possible that going forward, fewer patients with COVID-19 will develop profound respiratory failure, given the findings from the RECOVERY trial[@bib6] showing reduced mortality in patients with COVID-19 who were ventilated and given dexamethasone. Notably, only 12 (14%) patients in the study of Schmidt and colleagues received corticosteroids before ECMO day 8. There was a high incidence of pulmonary embolism during ECMO (16 \[19%\] patients) despite the authors selecting higher anticoagulation targets than would typically be used for patients with ARDS that is not associated with COVID-19. This finding highlights the importance of the coagulation system in patients with COVID-19 in general, and specifically highlights the need to investigate anticoagulation targets during ECMO in these patients.

There are substantially more [extracorporeal life support organisation (ELSO)](https://www.elso.org/default.aspx){#interrefs10} registered ECMO centres today than existed during the 2009 influenza A (H1N1) pandemic (430 centres *vs* 164 centres), and this number will probably increase. How do we ensure that quality of care is adequate on a large scale, especially during the stress of pandemics? One approach is to adopt the ELSO guidance for responsible ECMO use.[@bib7], [@bib8] Another is to concentrate ECMO activity in dedicated high-volume centres enabled by mobile ECMO teams, a model followed by the Paris--Sorbonne University Hospital Network, which delivered comprehensive pre-ECMO management and judicious patient selection.

With the presented data in hand, is there a need for randomised trials of ECMO specific to ARDS associated with COVID-19? From a strictly academic perspective, it could be argued that they are needed. However, large randomised trials would be difficult to do during the pandemic, and although there is controversy,[@bib9] it might be that ARDS associated with COVID-19 is similar to ARDS not associated with COVID-19 from a mechanics and gas exchange perspective[@bib1], [@bib9] (although perhaps not from a coagulation perspective).

In the meantime, the more important question concerns the degree to which ECMO should be used in ARDS associated with COVID-19 given the resources required. In the study by Schmidt and colleagues, the median length of ECMO support (20 days) and ICU length of stay (36 days) was very high (compared with a median of 11 days of ECMO support and 23 days in ICU in the EOLIA trial[@bib4]). The scale and quality of ECMO care, if replicated in other jurisdictions, might potentially save lives; however, clearly at a cost in terms of resources and potential complications.[@bib10] Any decisions on whether and when to use ECMO for very severe COVID-19 would have to be made locally with a clear recognition of the extensive resources required (mainly human resources), the expected caseload, and the potential implications for other patients.
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